Dr. Judy Chou @biologicsiscool to deliver a keynote titled “The Pursuit of Excellence in Innovative Biologics” at the 17th Annual Bio Innovation Leaders Summit, February 12th, in Singapore to discuss advanced technologies required in innovative biologics to truly benefit patients

Our leadership team had great discussions with the physician leaders at National Taiwan University Hospital, experts in #InflammatoryBowelDisease. United by a passion for science & a commitment to helping patients with immunological diseases, we’re grateful for this partnership.

Our President and CEO, Dr. Judy Chou and AltruBio’s Leadership Team visited the National Biotechnology Research Park (NBRP), a renowned institute focused on research and translational sciences for biomedical development in Taiwan. We look forward to future collaboration.

AltruBio recently hosted an Investigator Meeting for our phase 2a study in #UlcerativeColitis (UC). We’re grateful to the investigators, study coordinators, nurses & other site staff for their crucial contributions as we develop this novel therapy for patients suffering from UC.

At AltruBio, we're proud to call San Francisco Bay Area home—the birthplace of the Biotech industry. Read more about why this biotech hub gives us a competitive edge in this @DDWJournal article: bit.ly/3YdXSJf

Dr. Judy Chou, President & CEO of @AltruBioInc will be speaking at BIO Investor Forum, October 15 in San Francisco, during the session “Standing Out from the Crowd: How to Capture Investor Attention in Competitive Fields”. Learn more here: bif.bio.org/ #BIF2024

AltruBio, a clinical-stage biotech company developing novel Immune Checkpoint Enhancers (ICE) aimed at treating unmet medical needs of patients with immunological and inflammatory diseases will participate at the Leerink Partners Biopharma Private Company Connect, Oct. 22, 2024.

Our leadership team recently visited our research group in Taiwan. As one team, we embrace open-minded thinking in a fun, creative, and supportive environment, working together to bring innovative treatments to patients. Being together was truly inspiring! #AltruBioCulture

Our President and CEO, Dr. Judy Chou has contributed one of the featured articles in the latest @DrugTargetRev report titled "Leveraging agonist antibodies to address immunological diseases”. Read the article here: bit.ly/DTR102024

It was such an honor to be one of the finalists in the Emerging Innovation category for the prestigious @CALifeSciences #Pantheon2024 Awards and to be recognized among the innovative biotech companies at last night’s 21stAnnual Pantheon Awards ceremony.

We are invited to attend the upcoming @Jefferies Healthcare Conference 2024 in London, Nov 19-21 & our President and CEO, Dr. Judy Chou will present at the @PiperSandler Annual Healthcare Conference 2024 in New York City, Dec. 3-5. Learn more here: bit.ly/3YMW3Ck

We’re excited to share that AltruBio has been named a @BioSpace 2025 Best Places to Work honoree for the 3rd year in a row, recognized as one of the top 30 small biopharma employers based on votes from thousands of life science community members. Link: bit.ly/40J1FzX

Our President and CEO Dr. Judy Chou is invited to the @APEC_CEOsummit 2024, Nov 13-15 in Lima, Peru. Bringing together CEOs, entrepreneurs, & thought leaders, the Summit provides a platform for exchanging ideas, collaboration & relationship building. Link: bit.ly/48IhMjn

We presented new data for ALT-268 at the 9th FIMSA 2024 Congress in Taipei, demonstrating ALT-268’s in vivo activity and mechanism of action as an immune checkpoint enhancer, supporting its further clinical development for #UlcerativeColitis. Read more: bit.ly/3AsoYDk

With our recently closed fundraising, we are excited to move forward with our novel immune checkpoint enhancer (ICE) ALTB-268 in ulcerative colitis phase 2 program. Read more about AltruBio’s progress: bit.ly/4bX4BeC

What a fantastic four years it’s been for AltruBio! We’ve enjoyed the journey together with our shared commitment and passion to improving patients’ lives. We are looking forward to progressing further on our Phase 2 trials in ulcerative colitis!

Our recent Series B was listed among the top 10 private financings in 1H2024 and the largest in its round by @endpts. This funding will bring our innovative #ICE agonist antibody to patients suffering from immunological & inflammatory diseases. Read more: bit.ly/4bGvkvw

On Sept 13, CEO, Dr. Judy Chou will share her career journey at Chang Gung University, Taiwan, including her leadership roles in academia and large pharma to now, the CEO of a biopharma company, @AltruBioInc .